1st French-Israeli International Conference on B Cells and therapeutic antibodies

References

• Wang M, Yang Z, Rada C, Neuberger MS. AID upmutants isolated using a high-throughput screen highlight the immunity/cancer balance limiting DNA deaminase activity. Nat Struct Mol Biol 2009; 16:769 - 76; http://dx.doi.org/10.1038/nsmb.1623; PMID: 19543289
   PubMed Web of Science ®Google Scholar
• Steinitz M. Three decades of human monoclonal antibodies: past, present and future developments. Hum Antibodies 2009; 18:1 - 10; PMID: 19478393
   PubMedGoogle Scholar
• Dogan I, Bertocci B, Vilmont V, Delbos F, Mégret J, Storck S, et al. Multiple layers of B cell memory with different effector functions. Nat Immunol 2009; 10:1292 - 9; http://dx.doi.org/10.1038/ni.1814; PMID: 19855380
   PubMed Web of Science ®Google Scholar
• Keren Z, Naor S, Nussbaum S, Golan K, Itkin T, Sasaki Y, et al. B-cell depletion reactivates B lymphopoiesis in the BM and rejuvenates the B lineage in aging. Blood 2011; 117:3104 - 12; http://dx.doi.org/10.1182/blood-2010-09-307983; PMID: 21228330
   PubMed Web of Science ®Google Scholar
• Shachar I, Haran M. The secret second life of an innocent chaperone: the story of CD74 and B cell/chronic lymphocytic leukemia cell survival. Leuk Lymphoma 2011; 52:1446 - 54; http://dx.doi.org/10.3109/10428194.2011.565437; PMID: 21417823
   PubMed Web of Science ®Google Scholar
• Peled JU, Kuang FL, Iglesias-Ussel MD, Roa S, Kalis SL, Goodman MF, et al. The biochemistry of somatic hypermutation. Annu Rev Immunol 2008; 26:481 - 511; http://dx.doi.org/10.1146/annurev.immunol.26.021607.090236; PMID: 18304001
   PubMed Web of Science ®Google Scholar
• Kwakkenbos MJ, Diehl SA, Yasuda E, Bakker AQ, van Geelen CMM, Lukens MV, et al. Generation of stable monoclonal antibody-producing BCR+ human memory B cells by genetic programming. Nat Med 2010; 16:123 - 8; http://dx.doi.org/10.1038/nm.2071; PMID: 20023635
   PubMed Web of Science ®Google Scholar
• Jin A, Ozawa T, Tajiri K, Obata T, Kondo S, Kinoshita K, et al. A rapid and efficient single-cell manipulation method for screening antigen-specific antibody-secreting cells from human peripheral blood. Nat Med 2009; 15:1088 - 92; http://dx.doi.org/10.1038/nm.1966; PMID: 19684583
   PubMed Web of Science ®Google Scholar
• Olivier S, Jacoby M, Brillon C, Bouletreau S, Mollet T, Nerriere O, et al. EB66 cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic monoclonal antibodies with enhanced ADCC activity. MAbs 2010; 2:405 - 15; PMID: 20562528
   PubMed Web of Science ®Google Scholar
• Mostoslavsky R, Singh N, Tenzen T, Goldmit M, Gabay C, Elizur S, et al. Asynchronous replication and allelic exclusion in the immune system. Nature 2001; 414:221 - 5; http://dx.doi.org/10.1038/35102606; PMID: 11700561
   PubMed Web of Science ®Google Scholar
• Laskov R, Yahud V, Hamo R, Steinitz M. Preferential targeting of somatic hypermutation to hotspot motifs and hypermutable sites and generation of mutational clusters in the IgVH alleles of a rheumatoid factor producing lymphoblastoid cell line. Mol Immunol 2011; 48:733 - 45; http://dx.doi.org/10.1016/j.molimm.2010.10.009; PMID: 21194753
   PubMed Web of Science ®Google Scholar
• Jeevan-Raj BP, Robert I, Heyer V, Page A, Wang JH, Cammas F, et al. Epigenetic tethering of AID to the donor switch region during immunoglobulin class switch recombination. J Exp Med 2011; 208:1649 - 60; http://dx.doi.org/10.1084/jem.20110118; PMID: 21746811
   PubMed Web of Science ®Google Scholar
• Rouaud P, Vincent-Fabert C, Fiancette R, Cogné M, Pinaud E, Denizot Y. Enhancers located in heavy chain regulatory region (hs3a, hs1,2, hs3b, and hs4) are dispensable for diversity of VDJ recombination. J Biol Chem 2012; 287:8356 - 60; http://dx.doi.org/10.1074/jbc.M112.341024; PMID: 22270371
   PubMed Web of Science ®Google Scholar
• Roulland S, Faroudi M, Mamessier E, Sungalee S, Salles G, Nadel B. Early steps of follicular lymphoma pathogenesis. Adv Immunol 2011; 111:1 - 46; http://dx.doi.org/10.1016/B978-0-12-385991-4.00001-5; PMID: 21970951
   PubMed Web of Science ®Google Scholar
• Makdasi E, Fischel R, Kat I, Eilat D. Autoreactive anti-DNA transgenic B cells in lupus-prone New Zealand black/New Zealand white mice show near perfect L chain allelic exclusion. J Immunol 2009; 182:6143 - 8; http://dx.doi.org/10.4049/jimmunol.0803610; PMID: 19414767
   PubMed Web of Science ®Google Scholar
• Pfirsch-Maisonnas S, Aloulou M, Xu T, Claver J, Kanamaru Y, Tiwari M, et al. Inhibitory ITAM signaling traps activating receptors with the phosphatase SHP-1 to form polarized “inhibisome” clusters. Sci Signal 2011; 4:ra24; http://dx.doi.org/10.1126/scisignal.2001309; PMID: 21505186
   PubMed Web of Science ®Google Scholar
• Beck A, Wurch T, Bailly C, Corvaïa N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10:345 - 52; http://dx.doi.org/10.1038/nri2747; PMID: 20414207
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298 - 306; http://dx.doi.org/10.1038/nrc3245; PMID: 22419253
   PubMed Web of Science ®Google Scholar
• Turley EA, Naor D. RHAMM and CD44 peptides-analytic tools and potential drugs. Front Biosci 2012; 17:1775 - 94; http://dx.doi.org/10.2741/4018; PMID: 22201835
   PubMed Web of Science ®Google Scholar
• Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008; 14:3044 - 51; http://dx.doi.org/10.1158/1078-0432.CCR-07-4079; PMID: 18483370
   PubMed Web of Science ®Google Scholar
• Marcus A, Eshhar Z. Tumor-specific allogeneic cells for cancer therapy. Expert Opin Biol Ther 2011; 11:1551 - 4; http://dx.doi.org/10.1517/14712598.2011.628934; PMID: 21995504
   PubMed Web of Science ®Google Scholar
• de Romeuf C, Dutertre CA, Le Garff-Tavernier M, Fournier N, Gaucher C, Glacet A, et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. Br J Haematol 2008; 140:635 - 43; http://dx.doi.org/10.1111/j.1365-2141.2007.06974.x; PMID: 18302712
   PubMed Web of Science ®Google Scholar
• Vaks L, Benhar I. In vivo characteristics of targeted drug-carrying filamentous bacteriophage nanomedicines. J Nanobiotechnology 2011; 9:58; http://dx.doi.org/10.1186/1477-3155-9-58; PMID: 22185583
   PubMed Web of Science ®Google Scholar
• Sela-Passwell N, Kikkeri R, Dym O, Rozenberg H, Margalit R, Arad-Yellin R, et al. Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential. Nat Med 2012; 18:143 - 7; http://dx.doi.org/10.1038/nm.2582; PMID: 22198278
   PubMed Web of Science ®Google Scholar
• Kirchhofer A, Helma J, Schmidthals K, Frauer C, Cui S, Karcher A, et al. Modulation of protein properties in living cells using nanobodies. Nat Struct Mol Biol 2010; 17:133 - 8; http://dx.doi.org/10.1038/nsmb.1727; PMID: 20010839
   PubMed Web of Science ®Google Scholar
• Dahan R, Reiter Y. T-cell-receptor-like antibodies - generation, function and applications. Expert Rev Mol Med 2012; 14:e6; http://dx.doi.org/10.1017/erm.2012.2; PMID: 22361332
   PubMedGoogle Scholar
• Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, Sica A, et al. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol 2009; 182:4415 - 22; http://dx.doi.org/10.4049/jimmunol.0713732; PMID: 19299742
   PubMed Web of Science ®Google Scholar
• Abès R, Gélizé E, Fridman WH, Teillaud JL. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 2010; 116:926 - 34; http://dx.doi.org/10.1182/blood-2009-10-248609; PMID: 20439625
   PubMed Web of Science ®Google Scholar
• Gadri Z, Kukulansky T, Bar-Or E, Haimovich J, Hollander N. Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma. J Immunother 2009; 32:333 - 40; http://dx.doi.org/10.1097/CJI.0b013e31819b7c17; PMID: 19342972
   PubMed Web of Science ®Google Scholar
• Pham T, Bachelez H, Berthelot JM, Blacher J, Bouhnik Y, Claudepierre P, et al. TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 2011; 78:Suppl 1 15 - 185; http://dx.doi.org/10.1016/S1297-319X(11)70001-X; PMID: 21703545
   PubMed Web of Science ®Google Scholar
• Papp K, Menter A, Poulin Y, Gu Y, Sasso EH. Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study. [Epub ahead of print] J Eur Acad Dermatol Venereol 2012; •••; http://dx.doi.org/10.1111/j.1468-3083.2012.04515.x; PMID: 22429586
   PubMed Web of Science ®Google Scholar
• Burioni R, Canducci F, Mancini N, Clementi N, Sassi M, De Marco D, et al. Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV). Virology 2010; 399:144 - 52; http://dx.doi.org/10.1016/j.virol.2009.12.014; PMID: 20096915
   PubMed Web of Science ®Google Scholar
• Breden F, Lepik C, Longo NS, Montero M, Lipsky PE, Scott JK. Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease. AIDS 2011; 25:1247 - 57; PMID: 21508803
   PubMed Web of Science ®Google Scholar